FDA accepts Teva ecopipam NDA for pediatric Tourette syndrome, grants priority review

Reuters2026/08/19 12:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA accepted Teva’s NDA for ecopipam to treat pediatric Tourette syndrome, granting priority review.
PDUFA action date set for late Q1 2027.
Ecopipam is a first-in-class selective D1 receptor antagonist with orphan drug designation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608190830OMX_____CNEWS_EN_GNW1001258273_en) on August 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

FDA accepts Teva ecopipam NDA for pediatric Tourette syndrome, grants priority review

You may also like

Crypto prices